CRISPR Therapeutics AG

11/09/2026 | Press release | Distributed by Public on 11/09/2026 08:22

CRISPR Therapeutics Presents Phase 1b Data for CTX310 Demonstrating Reductions in ANGPTL3 and Triglycerides in Patients with Severe Hypertriglyceridemia at the American Heart[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.
CRISPR Therapeutics AG published this content on November 09, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 09, 2026 at 14:22 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]